Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization‐defined chromosome 13 deletion in multiple myeloma: early results of total therapy II
Open Access
- 20 December 2002
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 120 (1), 44-52
- https://doi.org/10.1046/j.1365-2141.2003.03948.x
Abstract
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.Keywords
This publication has 25 references indexed in Scilit:
- High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusionsBlood, 2001
- Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapyBlood, 2001
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Total Therapy With Tandem Transplants for Newly Diagnosed Multiple MyelomaBlood, 1999
- MULTIPLE MYELOMA: ALMOST ALL PATIENTS ARE CYTOGENETICALLY ABNORMALBritish Journal of Haematology, 1996
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaNew England Journal of Medicine, 1996
- Cytogenetic findings in 200 patients with multiple myelomaCancer Genetics and Cytogenetics, 1995
- Cytoplasmic immunoglobulin content in multiple myeloma.JCI Insight, 1985
- A multivariate analysis of the risk of coronary heart disease in FraminghamJournal of Chronic Diseases, 1967
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958